130 related articles for article (PubMed ID: 28093719)
1. Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
Br J Surg; 2017 Mar; 104(4):408-417. PubMed ID: 28093719
[TBL] [Abstract][Full Text] [Related]
2. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
[TBL] [Abstract][Full Text] [Related]
3. Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
Findlay JM; Gillies RS; Franklin JM; Teoh EJ; Jones GE; di Carlo S; Gleeson FV; Maynard ND; Bradley KM; Middleton MR
Eur Radiol; 2016 Oct; 26(10):3519-33. PubMed ID: 26883329
[TBL] [Abstract][Full Text] [Related]
4. Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.
Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
J Nucl Med; 2017 Feb; 58(2):266-275. PubMed ID: 27635027
[TBL] [Abstract][Full Text] [Related]
5. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
[TBL] [Abstract][Full Text] [Related]
6. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Gillies RS; Middleton MR; Han C; Marshall RE; Maynard ND; Bradley KM; Gleeson FV
Br J Surg; 2012 Feb; 99(2):239-45. PubMed ID: 22329010
[TBL] [Abstract][Full Text] [Related]
7. Routinely staging gastric cancer with
Findlay JM; Antonowicz S; Segaran A; El Kafsi J; Zhang A; Bradley KM; Gillies RS; Maynard ND; Middleton MR
Eur Radiol; 2019 May; 29(5):2490-2498. PubMed ID: 30643947
[TBL] [Abstract][Full Text] [Related]
8. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
9. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer.
Miyata H; Yamasaki M; Takahashi T; Murakami K; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Br J Surg; 2013 Oct; 100(11):1490-7. PubMed ID: 24037571
[TBL] [Abstract][Full Text] [Related]
10. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
[TBL] [Abstract][Full Text] [Related]
11. Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy.
Jimenez-Jimenez E; Mateos P; Ortiz I; Aymar N; Roncero R; Gimenez M; Pardo J; Sabater S
Clin Transl Oncol; 2019 Sep; 21(9):1159-1167. PubMed ID: 30661172
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
13. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Role of Pre-operative Positron Emission Tomography-Computed Tomography and Endoscopic Ultrasound Parameters in Oesophageal Adenocarcinoma.
Dellaportas D; Zylstra J; Gossage J; Baker C; Kelly M; Hemelrijck MV; Griffin N; Lagergren J; Davies AR
Chirurgia (Bucur); 2019; 114(4):443-450. PubMed ID: 31511130
[No Abstract] [Full Text] [Related]
15. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
Elliott JA; O'Farrell NJ; King S; Halpenny D; Malik V; Muldoon C; Johnston C; Reynolds JV
Br J Surg; 2014 Dec; 101(13):1702-11. PubMed ID: 25351460
[TBL] [Abstract][Full Text] [Related]
16. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
17. Intra-tumor metabolic heterogeneity of gastric cancer on
Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
[TBL] [Abstract][Full Text] [Related]
18. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
[TBL] [Abstract][Full Text] [Related]
19. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
20. PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.
Yuan H; Tong DK; Vardhanabhuti V; Law SY; Chiu KW; Khong PL
Nucl Med Commun; 2016 Sep; 37(9):947-55. PubMed ID: 27145438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
